DOACs or VKAs or LMWH - What is the optimal regimen for cancer-associated venous thromboembolism? A systematic review and meta-analysis.

4.4 Pulmonary embolism (PE) The DOAC therapy does reduce the incidence of PE in patients with active cancer compared to LMWH but there was borderline significant difference between the DOAC and LMWH groups in the incidence of pulmonary embolism amongst cancer patients (Hazard ratio [HR] 0.71, 95% confidence interval [CI] 0.47–1.06; P = 0.10; I 2 = 7%) ( Fig. 4 ). 4.5 All-cause mortality Pooled analysis shows a lower rate of mortality in patients treated with DOACs compared to conventional therapy of either VKA or LMWH, however, no statistically significant difference was found between the two groups of cancer patients.

also in 11,409 other papers

Secondly, DOACs have also shown borderline significance in reducing the risk of developing PE as well as reducing mortality rates amongst all cancer patients ( Fig. 4 , Fig. 5 ).

also in 7,017 other papers